Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
Abstract CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is to characterize the impact of chemotherapy according to histology in patients diagnosed with M...
Guardado en:
Autores principales: | Susana Cedres, Juan-David Assaf, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, David Marmolejo, Alejandra Rezqallah, Caterina Carbonell, Joan Frigola, Ramon Amat, Anna Pedrola, Rodrigo Dienstmann, Enriqueta Felip |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dda7bac31e5741c2aadbfeb55a39dc46 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cytomegalovirus infection in malignant pleural mesothelioma.
por: DeVon Hunter-Schlichting, et al.
Publicado: (2021) -
Modern management of malignant pleural mesothelioma
por: Patel SC, et al.
Publicado: (2016) -
Integrated genomics point to immune vulnerabilities in pleural mesothelioma
por: Anca Nastase, et al.
Publicado: (2021) -
Malignant Pleural Mesothelioma Nodal Status: Where Are We at?
por: Sara Ricciardi, et al.
Publicado: (2021) -
Clinical staging of malignant pleural mesothelioma: current perspectives
por: Bonomi M, et al.
Publicado: (2017)